Inventiva S.A. American Depository Shares (IVA) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-01, Inventiva S.A. American Depository Shares (NASDAQ: IVA) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $3.73 (+0.54% 1D, market cap $881.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, IVA ranks #188 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IVA carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ALMS (Alumis Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $891.8M) and OBX (Obsidian Therapeutics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $896.9M). Among the 5-stock peer group, IVA leads on earnings multiple (N/A) while ALMS leads on capital efficiency (-35.0% ROIC).
For Inventiva S.A. American Depository Shares (IVA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #188 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 20% of 52W Range • RSI-14 at 53.8 (NEUTRAL RANGE)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
Even with a 61/100 (C-) score, IVA faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($3.82) or 200D SMA ($4.88) invalidates the momentum regime and cuts Target Base ($3.78) toward Bear Floor ($2.95).
Inventiva S.A. American Depository Shares (IVA) advanced +0.54% to $3.73, trading at 20% of its 52-week range ($2.82 – $7.29). Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
Is IVA a good stock to buy? We came across a bullish thesis on Inventiva S.A. on BioEquity Watch’s Substack. Since the thesis was published on July 31st, IVA shares have pulled back as investors weigh the upcoming Phase
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IVA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IVA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Inventiva S.A. American Depository Shares (IVA) ranks #188 by composite RQD confidence (61/100, grade C-) and #379 by equity capitalization ($881.3M). Within this direct 5-issuer industry benchmark cohort, IVA leads on earnings valuation at N/A trailing P/E, while ALMS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IVA currently leads its immediate peer cohort in composite quantitative strength at 61/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IVA
ACTIVE
Inventiva S.A. American Depository Shares | C- | 61/100 | — | — | — | +0.54% | $881.3M | Benchmark Subject |
| ALMS Alumis Inc. | E | 23/100 | — | — | -35.0% | -3.37% | $891.8M | /alms-vs-iva → |
| OBX Obsidian Therapeutics Inc. | D- | 39/100 | — | — | -35.0% | -0.48% | $896.9M | /obx-vs-iva → |
| CRVS Corvus Pharmaceuticals Inc. | E | 31/100 | — | — | -35.0% | -2.76% | $860.6M | /crvs-vs-iva → |
| JBIO Jade Biosciences Inc. | D- | 36/100 | — | — | -35.0% | -2.40% | $905.6M | /jbio-vs-iva → |
Inventiva S.A. American Depository Shares (IVA) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $881.3M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-01, Inventiva S.A. American Depository Shares (NASDAQ: IVA) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $3.73 (+0.54% 1D, market cap $881.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, IVA ranks #188 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IVA carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ALMS (Alumis Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $891.8M) and OBX (Obsidian Therapeutics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $896.9M). Among the 5-stock peer group, IVA leads on earnings multiple (N/A) while ALMS leads on capital efficiency (-35.0% ROIC).
For Inventiva S.A. American Depository Shares (IVA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #188 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
IVA last traded at $3.73 (+0.54% on volume of 1,435,337 shares), positioning the stock -2.36% below its 50-day simple moving average ($3.82) and -23.57% below its 200-day simple moving average ($4.88). Across its 52-week range of $2.82 to $7.29, IVA sits at the 20.4% percentile with a 14-day RSI of 53.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.26 to $4.20).
Why IVA Stock advanced +0.54% Today — RQD Quant Desk Flash. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.